Addition of thiotepa and rituximab to antimetabolites significantly improves outcome in primary CNS lymphoma: first randomization of the IELSG32 trial.

Addition of thiotepa and rituximab to antimetabolites significantly improves outcome in primary CNS lymphoma: first randomization of the IELSG32 trial. Clin Adv Hematol Oncol. 2015 Aug;13(8 Suppl 9):10-1 Authors: Moskowitz CH PMID: 26452083 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research